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INTRODUCTION
Bladder and kidney cancer are the ninth 
and 15th most common cancers worldwide, 
respectively. In the UK, bladder and kidney 
cancers each account for approximately 
3% of new cancer cases, and 5300 and 
4500 annual deaths, with their incidence 
expected to rise.1,2 Early-stage diagnosis is 
strongly correlated with improved survival 
rates for both bladder and kidney cancer.1,2
The majority of bladder and kidney 
cancers (75% and 59%, respectively) are 
diagnosed following a referral from primary 
care in the UK.1–3 A prolonged primary 
care interval (from patient presentation to 
referral) is associated with worse clinical 
outcomes.4,5 Currently, in England, median 
diagnosis time for bladder and kidney 
cancer — after presentation in primary care 
with a relevant clinical feature — is 51 and 
70 days, respectively, with variation seen by 
symptom.6 
Visible haematuria (VH) is present in the 
majority of patients with bladder cancer 
(53%), however, it is less common in 
individuals diagnosed with kidney cancer 
(18%).7 Currently, the National Institute 
for Health and Care Excellence guidelines 
advise urgent referral for suspected 
bladder or kidney cancer for unexplained 
non-visible haematuria (NVH) or persistent 
VH in all individuals aged 60 and 45 years, 
respectively.8 Although 5.1% of people with 
VH in a primary care setting are ultimately 
diagnosed with urological cancers, the 
positive predictive value (PPV) of NVH is 
less certain and may be as low as 1.6% in 
primary care.7 The focus on haematuria 
may impede early identification of cancers 
that present atypically or with a number 
of non-specific symptoms.6,9 This could 
also lead to the over-referral of lower-risk 
individuals presenting with haematuria.10
Risk assessment tools have the potential 
to improve timely diagnosis of cancer by 
combining multiple clinical features to 
identify symptomatic patients who would 
benefit from early referral and reducing 
investigations in individuals least likely to 
benefit.7,11 Risk models to guide clinical 
decision making are becoming more 
common. For example, the QCancer tool, 
which estimates the risk of 11 cancers based 
on symptoms and patient characteristics, 
has been integrated into primary care 
software.12 Although not routinely used to 
aid referral decisions for suspected cancer, 
risk assessment tools have been identified 




Timely diagnosis of bladder and kidney cancer 
is key to improving clinical outcomes. Given 
the challenges of early diagnosis, models 
incorporating clinical symptoms and signs 
may be helpful to primary care clinicians when 
triaging at-risk patients. 
Aim
To identify and compare published models that 
use clinical signs and symptoms to predict the 





A search identified primary research reporting 
or validating models predicting the risk of 
bladder or kidney cancer in MEDLINE and 
EMBASE. After screening identified studies 
for inclusion, data were extracted onto a 
standardised form. The risk models were 
classified using TRIPOD guidelines and 
evaluated using the PROBAST assessment tool. 
Results
The search identified 20 661 articles. Twenty 
studies (29 models) were identified through 
screening. All the models included haematuria 
(visible, non-visible, or unspecified), and seven 
included additional signs and symptoms (such 
as abdominal pain). The models combined 
clinical features with other factors (including 
demographic factors and urinary biomarkers) to 
predict the risk of undiagnosed prevalent cancer. 
Several models (n = 13) with good discrimination 
(area under the receiver operating curve >0.8) 
were identified; however, only eight had been 
externally validated. All of the studies had either 
high or unclear risk of bias.
Conclusion
Models were identified that could be used in 
primary care to guide referrals, with potential 
to identify lower-risk patients with visible 
haematuria and to stratify individuals who 
present with non-visible haematuria. However, 
before application in general practice, external 
validations in appropriate populations are 
required. 
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In this review, published models that 
incorporate symptoms and signs (referred 
to as clinical features) and estimate the 
risk of undiagnosed prevalent bladder or 
kidney cancer at an individual level were 
systematically identified and compared. The 
review focuses on the risk factors included 
in the models, the performance of the 
models (discrimination and calibration), 
and their potential use in primary care.
METHOD
A systematic review was performed 
following an a priori established study 
protocol (PROSPERO ID: CRD42018116967). 
An electronic literature search of 
MEDLINE and EMBASE was performed in 
November 2018 and updated in December 
2020. Literature published 1980–2020 was 
included, using a combination of subject 
headings incorporating ‘bladder or renal/
kidney or urinary-tract cancer’, ‘risk or risk 
factor or chance’ and ‘model or prediction 
or score’ (see Supplementary Table S1 
and S2). 
Studies were included that fulfil all of the 
following criteria:
• are published, peer-reviewed, primary 
research; 
• present a model, which here is considered 
the use of a combination of ≥2 factors to 
identify individuals with a higher risk of 
undiagnosed prevalent bladder or kidney 
cancer. Studies predicting recurrent or 
future risk were excluded;
• incorporate at least one clinical feature 
as a risk factor;
• include at least one quantitative measure 
of model performance (discrimination, 
calibration, or accuracy). Accepted 
measures include (but are not limited to) 
area under the receiver operating curve 
(AUROC), R 2 (goodness of fit), sensitivity, 
specificity, PPVs, and negative predictive 
values (NPVs). Graphical measures alone 
were not accepted; and
• are applicable to the general population. 
Studies including only specific groups — 
for example, individuals receiving dialysis 
— were excluded.
One reviewer carried out the search. 
Reviewers screened titles and abstracts 
to exclude clearly irrelevant articles. Pilot 
screening was carried out to ensure 
consistency between reviewers. The full 
text was examined, by two reviewers, if a 
definite decision to exclude could not be 
made based on the title and abstract alone. 
Disagreements were resolved by discussion 
with a third reviewer. 
Data extraction was carried out 
independently by two reviewers for all 
included studies. Where studies included 
multiple different models all were included 
separately. Details of model development, 
validation, and performance were extracted 
into a standardised form. Included studies 
were classified according to the TRIPOD 
guidelines.14 The PROBAST tool was used 
to assess risk of bias (RoB) over four 
domains of interest (population, risk factors, 
outcomes, and analysis).15,16 Information 
required for this assessment was extracted 
by two reviewers, and one reviewer scored 
the studies. A second reviewer checked the 
RoB assessment process. 
RESULTS
After duplicates were removed, the 
search identified 20 661 articles. Of 
these, 19 959 were excluded by title and 
abstract screening, and 686 after full-text 
assessment. Twenty studies were identified, 
describing 29 models that satisfied the 
inclusion criteria (Figure 1).10,17–35 
Study design and setting
Of the 20 studies, 16 were cohort 
studies10,17,19–30,33,34 and four were case–
control studies18,31,32,35 (see Supplementary 
Table S3). Six studies were performed in 
a UK primary care setting, using routinely 
coded data.22–24,31,32,35 Nine were conducted 
in secondary (or specialist) care settings, 
including hospital outpatient clinics and 
urology departments.10,18,21,26–28,30,33,34 The 
remaining five studies do not provide enough 
information about the study setting to be 
classified as primary or secondary17,19,20,25,29 
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How this fits in 
Timely diagnosis of bladder and kidney 
cancer from primary care is key to 
improving survival rates, but remains 
challenging. Risk models have been 
suggested as a possible tool to guide 
clinicians in making referral decisions, 
particularly in individuals who present 
atypically. This systematic review identified 
a number of models that may be of 
interest, in particular, models able to 
identify low-risk individuals who may not 
require referral and a model suitable for 
stratifying risk in individuals with non-visible 
haematuria. However, only a small number 
of models included clinical features other 
than haematuria and there was a lack of 
external validations. 
(for example, referring to recruitment at a 
‘clinic’). 
Most studies included European (n = 11) 
or North American populations (n = 8); two 
studies were based in South East Asia.21,26 
The six studies in a primary care setting 
included a mixture of asymptomatic and 
symptomatic individuals.22–24,31,32,35 Eleven 
studies included patients undergoing 
investigation for haematuria,10,18–21,26,27,28,30,33,34 
in some cases restricted to NVH (n = 2)27,34 
or painless haematuria (n = 4).18–20,26 Three 
studies included individuals classified 
as high-risk based on a prior history of 
haematuria30 or smoking status.17,29 One 
study included all individuals enrolled on 
a health insurance plan who underwent 
urinalysis.25
Of the 29 models (Table 1), the outcomes 
were a diagnosis of bladder cancer 
(n = 19),17–21,29,32–35 kidney cancer (n = 1),31 or 
urological cancer (n = 9) (bladder and kidney 
cancer, either with10,22,25 or without23,24,27,28 
cancers of the urothelium). Most models 
were developed in mixed-sex populations, 
although a small number were developed 
specifically for males (n = 2)22,23 and females 
(n = 2).22,24 The majority of the models were 
developed using logistic regression (n = 22), 
although other methodologies, including 
survival models (n = 2), were also found. 
Internal validation — either bootstrapping17–20 
or split-sampling (random22–24,34 or non-
random28,29) — has been carried out for 
22 models. Only eight models have been 
externally validated.10,25,27,28
Risk factors
Haematuria was included as a risk 
factor in all of the included models (see 
Supplementary Table S4). However, there 
was significant variation in the type of 
haematuria included. Four models used 
only VH,22,31,32 four only NVH,25,28,34 and 14 
included both (as separate risk factors 
[n = 2]25,35 or the degree of haematuria was 
used as a risk factor [n = 12]18–21,29,33). In 
seven models, the type of haematuria was 
unspecified.17,23,24 
Most studies (n = 14) reported the 
association between haematuria 
and the outcome of interest (see 
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MEDLINE
n = 14 139
EMBASE
n = 16 797
Articles after
duplicates removed
n = 20 660
Articles screened by
title and abstract
n = 20 660
Articles excluded

























Full-text articles excluded, with reasons
 n = 684
No full text available: 2
Not published in a peer-reviewed journal: 118
Not primary research: 41
Does not predict the development of a UTCa: 72
No measure of risk for individuals: 5
No measure of risk incorporating ≥2 factors: 190
Not appropriate for the general population: 25
No performance measures: 157











Figure 1. PRISMA flow diagram. UTCa = urinary tract 
cancer. 
Table 1. Summary of included models 
 Summary of risk factors
 Demographic and lifestyle Clinical symptoms and signs
Modela (author         Test  Development 
[ year],ref model) Outcome Age Sex Smoking Other Haematuria System specific Non-specific results Validationb setting
Hippisley-Cox KCa, BCa,  — — x x VH Abdominal Appetite loss,  — Internally P 
(2012),22 a UCa      pain weight loss,  
        anaemia
Hippisley-Cox KCa, BCa,  — — x x VH Abdominal Appetite loss,  — Internally P 
(2012),22 b UCa      pain weight loss,  
        anaemia
Hippisley- KCa, BCa x — x x Unspecified Abdominal Night sweats,  — Internally P 
Cox 2013),23 a       pain weight loss
 … continued
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Supplementary Table S5). Frequently the 
presence of haematuria, either any (n = 3), 
visible (n = 5), or non-visible (n = 2), was 
compared with no haematuria. One study 
reported the odds ratio (OR) separately for 
both VH (OR 26, 95% confidence interval 
[CI] = 22 to 30) and NVH (OR 20, 95% 
CI = 12 to 33) for bladder cancer.35 Four 
studies, developed in cohorts composed 
of individuals undergoing investigation for 
Table 1 continued. Summary of included models 
 Summary of risk factors
 Demographic and lifestyle Clinical symptoms and signs
Modela (author         Test  Development 
[ year],ref model) Outcome Age Sex Smoking Other Haematuria System specific Non-specific results Validationb setting
Hippisley- KCa, BCa x — x x Unspecified Abdominal pain,  Anaemia, appetite — Internally P 
Cox (2013),24 b       postmenopausal  loss, indigestion,  
       bleeding weight loss
Shephard KCa x — — — VH Back pain,  Fatigue,  x None P 
(2013),31 a       abdominal  constipation, 
       pain, UTI nausea
Shephard BCa x — — — VH Dysuria,  — x None P 
(2012)32       abdominal pain,  
       UTI
Price (2014)35 BCa x — — — VH and Dysuria,  Constipation x None P 
      NVH abdominal pain,  
       UTI
Jung (2011),25 a KCa, BCa,  x — — — VH or — — — Externally U 
 UCa     NVH
Jung (2011),25 b KCa, BCa,  x — — — NVH — — — Externally U 
 UCa
Loo (2013),28 a KCa, Bca x x x — NVH and  — — — Externally S 
      history
Loo (2013),28 b KCa, Bca x x x — NVH and  — — — Externally S 
      history
Beukers (2013),18 a BCa x x — — Degree — — x Internally S
Beukers (2013),18 b BCa x x — — Degree  — — x Internally S
Cha (2012),19 a BCa x x x — Degree  — — — Internally U
Cha (2012),19 b BCa x x x — Degree  — — x Internally U
Cha (2012),19 c BCa x x x — Degree  — — x Internally U
Cha (2012),19 d BCa x x x — Degree — — x Internally U
Hee (2013)21 BCa x x x — Degree  — — — Externally S
Lotan (2009),29 a BCa x x x x Degree — — — Internally U
Lotan (2009),29 b BCa x x x x Degree  — — x Internally U
Lotan (2009),29 c BCa x x x x Degree  — — x Externally U
Lotan (2009),29 d BCa x x x x Degree  — — x Internally U
Barbieri (2012),17 a BCa x x x x Unspecified — — — None U
Barbieri (2012),17 b BCa x x x x Unspecified — — x None U
Barbieri (2012),17 c BCa x x x x Unspecified — — x None U
Barbieri (2012),17 d BCa x x x x Unspecified — — x None U
Tan (2019)33 BCa x x x — Degree  — — — Externally S
Georgieva (2019)10 KCa, BCa,  x x x — History — — — Externally S 
 UCa
Matulewicz (2020)34 BCa x x x x NVH  — — — — S
aa, b, c refers to models developed by the same author group. bValidation: none — development only; internally — at least internally validated; and externally — externally validated. 
BCa = bladder cancer. degree = visible haematuria or non-visible haematuria. KCa = kidney cancer. NVH = non-visible (microscopic) haematuria. P = primary care. S = secondary 
care. U = unknown. UCa = cancer of the ureter. UTI = urinary tract infection. VH = visible (gross) haematuria. x = included in the model. 
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haematuria for suspected bladder cancer, 
gave ORs for individuals with VH compared 
with those with NVH.18,20,21,33 All showed 
stronger associations with VH than NVH 
(OR 1.71–3.85 in multivariate analysis). 
Seven models included other clinical 
features in addition to haematuria.22–24,31,32,35 
These included abdominal pain (n = 7), 
weight loss (n = 4), anaemia (n = 3), loss of 
appetite (n = 3), urinary tract infection (UTI) 
(n = 3), and dysuria (n = 3). In each case, the 
risk because of haematuria was at least 
eight times higher than the risk from all 
other clinical features.
Demographic risk factors, including age 
(n = 27), sex (n = 20), and ethnic group (n = 9), 
were used in most models. Modifiable lifestyle 
risk factors, including smoking (n = 24) and 
BMI (n = 2), were also considered. Three 
models included abnormal blood tests;31,32 
eight urine biomarkers17,18,20,29 and seven 
urine cytology.17,18,20,29
RoB
Most of the 20 studies included in this 
systematic review were assessed to have 
a high RoB (n = 17) in both development 
and validation (Figure 2). The most common 
issues were seen in domain 4 (analysis), 
in which 11 of 15 development studies and 
eight of 12 validation studies were at high 
RoB. This was frequently because of an 
insufficient number of cases or incomplete 
reporting of performance measures 
(including not reporting calibration of model). 
Performance measures
Discrimination (the AUROC) was 
reported for 26 models (Figure 3 and 
Supplementary  Table S6). Calibration was 
reported for 13 internal20,22–24,29,34 and three 
external validations.21,30,33 
The four Hippisley-Cox and Coupland 
models, developed in unfiltered population-
based cohorts to predict urological cancer, all 
have AUROC values in the range 0.88– 0.96 in a 
large internal validation (Figure 3, group D).22–
24 These models report good calibration and 
relatively high levels of accuracy (sensitivity 
0.77–0.71, specificity 0.90–0.91) when using 
the 90th percentile of risk as a cut-off. They 
also have high NPV (100%) for PPVs in the 
range 0.6%– 1.6% for this threshold. The two 
models developed for males have slightly 
higher discrimination than those for females. 
Demographic and lifestyle risk factors are 
combined with clinical features — smoking, 
haematuria, and abdominal pain feature in 
all four. Two specified VH as a symptom, 
whereas the other two did not specify type of 
haematuria. This did not significantly affect 
performance; however, other risk factors 
also differed between these models. 
The models by Shephard et al and 
Price et al predicted the risk of developing 
kidney31 and bladder32,35 cancer by 
combining pairs of symptoms observed in 
unfiltered population-based cohorts. The 
combinations of symptoms with the highest 
accuracy were microcytosis and abdominal 
pain for kidney cancer (PPV >5%), and VH 
and raised white blood cell count for bladder 
cancer (PPV 8.8%). It is shown35 that, even 
in older age groups (>60 years), the PPV 
of NVH for bladder cancer is low (0.8%), 
however, when combined with dysuria, for 
example, this increases to 4.5%. These 
symptom combinations are rare (<10 cases 
out of 3140 in development population), so 
may have limited impact individually. 
The model by Matulewicz et al34 was 
developed in a population with newly 
diagnosed NVH and had an AUROC value 
of 0.74 (95% CI = 0.67 to 0.80) in an internal 
validation (Figure 3, group A). This model 
combines a categorical measurement of 
NVH (red blood cells per high-power field 
[RBC/hpf]) with age, sex, smoking, and 
ethnic group to predict a likelihood of a 
bladder cancer diagnosis. For a threshold 
(>5% risk) that gives a PPV of 10.4%, 
reasonable accuracy (sensitivity 68%, 
specificity 75%) and a high NPV (98%) are 
demonstrated.
The remaining 20 models report 
discrimination in populations undergoing 
investigation for suspected urological 
cancer, with varying proportions of the 
populations having VH and NVH (Figure 3, 
groups B and C). On average, discrimination 
is higher in models developed only in 
Hee 2013 (1a)  –
Price 2014 (1a)  –
Shephard 2013 (1a)  –
Shephard 2012 (1a)  –
Barbieri 2012 (1b)  –
Beukers 2013 (1b)  –
Cha 2012 (1b)  –
Cha 2012 (1b)  –
Hippisley-Cox 2012 (2a)  –
Hippisley-Cox 2012 (2a)  –
Hippisley-Cox 2013 (2a)  –
Matulewicz 2020 (2a)  –
Loo 2013 (2b)  –
  Lotan 2009 (2b)  –
Tan 2019 (3)  –
Georgieva 2019 (4)  –
Jung 2011 (4)  –
Lee 2014 (4)  –
Lippmann 2017 (4)  –






D1 D2 D3 D4 Total
Figure 2. RoB assessment using PROBAST framework.a 
aFor each study, RoB is shown for model development 
and validation separately. RoB is assessed over four 
domains (D1: population, D2: risk factors, D3: outcome, 
D4: analysis), the overall results for each study are 
shown on the right. 1, 2, 3, and 4 refer to TRIPOD 
classification for each identified study.14 a, b, and c 
refer to models developed by the same author group. 
RoB = risk of bias.
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individuals with haematuria (group B) 
and in models that incorporate urinary 
biomarkers. The model with highest 
discrimination in external validation was 
Tan et al (2019) (AUROC = 0.77).33 This 
model combines type of haematuria with 
age, sex, and smoking status to predict 
the risk of a bladder cancer diagnosis. 
For an optimised cut-off point (>4.015%), 
the reported accuracy measures indicate 
high sensitivity (0.99) can be achieved; 
however, the corresponding specificity was 
low (0.31). The best performing models 
incorporating urinary biomarkers are 
Cha et al (2012) model c and Cha et al 
(2012) model d (AUROC = 0.9 in internal 
validation).19 The degree of haematuria (VH 
or NVH) is combined with the uCyt assay 
(an immunocytochemical test that detects 
markers from malignant urothelial cells 
in urine)36 and several demographic and 
lifestyle factors. Cha et al (2012) model d 
also included the results of cytology as a risk 
factor; this does not seem to improve model 
performance. The models by Loo et al 28 
include an indication of the severity of NVH 
(>25 RBC/hpf); Loo et al (2013) model b 




This review found 13 risk prediction models 
with good discrimination (>0.8) for urological 
cancer. All of the models included haematuria 
and seven incorporated additional clinical 
signs or symptoms. Most were developed 
in populations undergoing investigation for 
suspected urological cancer, with only seven 
developed in primary care (or unfiltered 
population-based) cohorts. Only eight of 
the identified models had been externally 
validated and around half (n = 14) had no 
reported measure of calibration.
Strengths and limitations
This is the first study, to the authors’ 
knowledge, to provide a systematic and 
up-to-date review of the existing risk 
prediction models for bladder or kidney 
cancer with application to primary care. 
The study benefits from a comprehensive 
search and rigorous screening of studies for 
inclusion. In total, 29 models were identified 
in this process, providing a clear overview 
of the current research in this area. The 
PROBAST tool was used, a new quality 
assessment tool for risk prediction models, 
to perform a robust assessment of the RoB 
for each model and identify areas where the 
quality of research is low. It was not possible 
to perform a meta-analysis because of the 
heterogeneity in the study designs, including 
differences in study type (development and 
validation), design (cohort and case–control), 
setting (primary and secondary care), and 
recruitment criteria. A further limitation is 
that several models used coded information 
from primary care records and may be 
subject to bias in clinician recording and 
choice of investigations.
Comparison with existing literature
Recent reviews have examined risk 
assessment tools for the identification of other 
undiagnosed cancers, including colorectal37 
and ovarian cancer.38 The models identified 
by those studies had similar discriminative 
ability to those described in this review. As in 
this review, a lack of high-quality studies and 
external validations was noted. There was a 
wider range of models developed specifically 
for primary care settings for those cancers, 
than have been identified in the current study 
for urological cancer.
Although VH has been widely shown 
to be associated with urological cancer,39 
the association with other clinical factors 
(including NVH and UTIs) is poorly 
understood,7,39 with variation between 
different populations.40 In this review, only 
seven models included clinical factors other 
than haematuria and only five studies directly 
compared VH and NVH as risk factors. 
Additionally, haematuria has a much higher 
contribution than other clinical risk factors in 
all models where >1 is used.
Implications for research and practice
The seven models developed in primary care 
settings22–24,31,32,35 are the most applicable 
to this review question. The excellent 
Figure 3. Model discrimination, AUROC.a 
aModels are split into groups describing the 
development population and within each group are 
ordered by the number of risk factors used. Study 
type (development, internal and external validation), 
type of haematuria used in model, and study setting 
are indicated on the plot. A, b, and c refer to models 
developed by the same author group. Each model is 
labelled according to its development study; however, 
the discrimination measured in several external 
validations26,27,30 of these models are also included in 
this summary plot (see supplementary Table S6 for 
details). AUROC = area under the receiver operating 
curve. NVH = non-visible haematuria. RF = risk factor. 
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performance of the four Hippisley- Cox 
models, if replicated in an external 
validation, would make them suitable for 
use in primary care, in particular, they 
may enable clinicians to identify lower-
risk individuals who do not need referral. 
However, it is unclear how these models 
would be used and how this would compare 
with current practice. For example, it cannot 
be inferred if any individuals currently 
eligible for referral (such as those with VH) 
would be reclassified using these models.
The model developed by Matulewizc,34 
in a population with newly identified NVH, 
could be used in primary care to guide 
referral decisions in individuals with NVH. 
Current guidelines for referral for suspected 
urological cancer in the UK differentiate 
between types of haematuria (VH and NVH) 
and age (>45 and >60 years, respectively). 
There is concern that lower-risk patients, 
such as younger individuals with NVH, are 
not managed optimally.7 The Matulewizc 
model, by combining a categorical measure 
of NVH with demographic factors, identifies 
both high- and low-risk individuals 
successfully (PPV 10.4% and NPV 98.2%). 
This suggests that this model could identify 
some individuals with NVH who are aged 
<60 years who would benefit from referral 
and some aged >60 years who are at lower 
risk and do not need referral. The high 
PPVs seen when using this model, and 
when NVH was combined with other clinical 
signs in the study by Price et al,35 indicate 
the need to consider the broader clinical 
context when making referral decisions in 
patients with NVH.
In conclusion, haematuria was the 
strongest clinical risk factor associated with 
urological cancers and was included in all 
of the models identified. Several models 
have been developed in primary care 
populations that could be used to guide 
referrals, in particular, identifying those at 
lower risk least likely to benefit from further 
investigation. Additionally, one model was 
identified that could be used to stratify the 
risk of cancer in individuals presenting with 
NVH. 
Future research in this area should initially 
focus on carrying out external validations of 
the identified models in a suitable primary 
care cohort. Researchers should then 
consider the impact that implementing 
these models to support referral decisions 
would have on both patient outcomes and 
the healthcare service in their analyses. 
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